
Laia Bernad Rosa
Graduated in Biotechnology at the Autonomous University of Barcelona and with great interest and vocation for virology, Laia has done internships during her undergraduate studies in the immunopathology group of the IGTP. Subsequently, she continued her training in the group of Infectious Pathologies and Antimicrobials at IMIM. Finally, she completed her academic training by completing the Master's degree in Virology at the Complutense University of Madrid, developing her Master's thesis at CISA, focused on the study of 3 vaccine candidates for bluetongue virus. Currently, she is part of the VIRIEVAC team at IrsiCaixa and has the support of the AGAUR-FI predoctoral grants program (2024 FI-3 00065) Joan Oró from the Secretariat for Universities and Research of the Department of Research and Universities of the Government of Catalonia and the European Social Fund Plus.
Safety and immunogenicity of PHH-1V booster against SARS-CoV-2 variants, including omicron subvariants: Results from a phase IIb open-label extension study.
Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.
Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results.